Published in Biotech Business Week, September 19th, 2005
APD356 is Arena's orally administered, internally discovered drug candidate for the treatment of obesity. On May 11, 2005, Arena announced that its phase IIa clinical trial demonstrated a highly statistically significant (p=0.0002) mean weight loss of 2.9 pounds in patients taking the 15 mg dose of APD356 versus 0.7 pounds for the placebo group over the 4 week...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.